<DOC>
	<DOCNO>NCT02183701</DOCNO>
	<brief_summary>The general aim clinical objective trial determine effect telmisartan 80 mg compare losartan 50 mg + HCTZ ( Hydrochlorothiazide ) 12.5 mg reduction blood pressure ( BP ) patient mild moderate hypertension assess 24 hour Ambulatory Blood Pressure Monitoring ( ABPM ) trough sit BP cuff measurement end treatment .</brief_summary>
	<brief_title>Telmisartan Compared Losartan + Hydrochlorothiazide Patients With Mild-to-moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Mildtomoderate essential hypertension define mean seat diastolic blood pressure measurement ≥ 95 mmHg measure manual cuff sphygmomanometer , Visit 2 fourweek placebo runin period ( baseline ) Mean seat systolic blood pressure ≥ 140 mmHg , measure manual cuff baseline ( Visit 2 ) A 24hour mean diastolic blood pressure , measure ABPM , ≥ 85 mmHg evaluate baseline ( Visit 3 ) Age 18 old Patient 's write informed consent accordance GCP ( Good Clinical Practice ) local legislation Premenopausal woman ( last menstruation ≤ 1 year prior date consent ) : Who surgically sterile ( hysterectomy , tubal ligation ) Who NOT practise acceptable mean birth control NOT plan continue use acceptable method throughout trial . Acceptable method birth control include IUD ( intrauterine device ) , oral , implantable injectable contraceptive Who positive urine pregnancy test Who nurse Mean seat diastolic blood pressure ( DBP ) &gt; 114 mmHg mean seat systolic BP &gt; 200 mmHg , manual cuff Any know hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( serum glutamate pyruvate transaminase ) ( ALT ) SGOT ( serum glutamate oxaloacetate transaminase ) ( AST ) great two time upper limit normal Serum creatinine &gt; 1.8 mg/dl ( 159 µmol/l ) Clinically relevant hypokalemia Known suspect secondary hypertension Known bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant patient , presence one functioning kidney . Congestive heart failure ( CHF ) ( NYHA ( New York Heart Association ) class CHF IIIIV ) Unstable angina within past 3 month ; stable angina change nitrate therapy ( dose frequency ) runin period require Stroke within past 6 month prior start runin period Myocardial infarction cardiac surgery within past 3 month prior start runin period PTCA ( percutaneous transluminal coronary angioplasty ) within past 3 month prior start runin period Previous history angioedema Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator Hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve Patients unstable insulindependent diabetes mellitus ( risk hypoglycemia HbA1c ≥ 10 % history within 6 month prior start runin period ) Known drug alcohol dependency within past 6 month period prior start runin period Concomitant administration medication know affect blood pressure , except medication allow protocol Patients receive investigational therapy within one month signing informed consent form Known hypersensitivity component formulation Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication Concomitant use lithium cholestyramine colestipol resin ( potential drug interaction HCTZ )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>